| scholarly article | Q13442814 |
| P2093 | author name string | David Kudrow | |
| James U Adelman | |||
| Jan Lewis Brandes | |||
| Pamela S Barrett | |||
| Shelly E Lener | |||
| C Phillip O'Carroll | |||
| Francis J O'Donnell | |||
| Stuart R Stark | |||
| Susan E Spruill | |||
| W James Alexander | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | migraine | Q133823 |
| P1104 | number of pages | 12 | |
| P304 | page(s) | 1443-1454 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Sumatriptan-naproxen for acute treatment of migraine: a randomized trial | |
| P478 | volume | 297 |
| Q44080477 | 2015 Headache Members' Choice Award |
| Q90569831 | A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches |
| Q37080223 | A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room |
| Q27025002 | A review of frovatriptan for the treatment of menstrual migraine |
| Q41642373 | Acute Migraine Therapy: New Drugs and New Approaches |
| Q34471863 | Acute Migraine Treatment in Adults |
| Q38704466 | Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review |
| Q37703842 | Acute Treatment of Migraine |
| Q37785210 | Acute treatment of migraine |
| Q41061643 | Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study |
| Q54443866 | Adding NSAIDs to triptans: could less be more? |
| Q37409505 | Allodynia in migraine: frequent random association or unavoidable consequence? |
| Q39316816 | Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia |
| Q37798757 | Are the current IHS guidelines for migraine drug trials being followed? |
| Q42961291 | Clinical trials report: sumatriptan-naproxen combination for symptomatic treatment of comorbid dysmenorrhea and migraine |
| Q33859031 | Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? |
| Q38927015 | Comparative tolerability of treatments for acute migraine: A network meta-analysis |
| Q34393819 | Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study |
| Q91967627 | Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine |
| Q46074175 | Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study |
| Q45131483 | Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination |
| Q34096610 | Current approaches to the diagnosis and management of paediatric migraine |
| Q46791913 | Current diagnosis and treatment of migraine |
| Q47653067 | Current management: migraine headache |
| Q37106936 | Current migraine management - patient acceptability and future approaches. |
| Q37695402 | Current practice and future directions in the prevention and acute management of migraine |
| Q38873658 | Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization |
| Q38167355 | Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs |
| Q44561102 | Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double-blind, crossover, multicenter, phase III clinical trial |
| Q33671824 | Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura |
| Q30844805 | Evidence and consensus recommendations for the pharmacological management of pain in India |
| Q36259763 | Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification |
| Q34409359 | Fixed-dose Sumatriptan/Naproxen Sodium Compared with each Monotherapy Utilizing the Novel Composite Endpoint of Sustained Pain-free/no Adverse Events |
| Q64113943 | From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses |
| Q37852640 | Headache in the emergency department |
| Q50795275 | How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. |
| Q44489814 | Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study |
| Q37798796 | Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine |
| Q39282412 | Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study |
| Q33160296 | Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. |
| Q39268172 | MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine |
| Q27006583 | Medication overuse in children and adolescents |
| Q49873285 | Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action |
| Q34655746 | Migraine and hormones: what can we be certain of? |
| Q37270897 | Migraine prevention trials and optimized acute therapy: translating lessons learned into clinical practice |
| Q39117083 | Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA. |
| Q39265773 | Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey |
| Q28276182 | NPS: Medical Consequences Associated with Their Intake |
| Q31135314 | NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data |
| Q24202983 | Naproxen with or without an antiemetic for acute migraine headaches in adults |
| Q30831647 | Network meta-analysis of migraine disorder treatment by NSAIDs and triptans |
| Q36332611 | New drugs for migraine |
| Q56363416 | Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study |
| Q47787596 | Novel Therapeutic Targets Against Spreading Depression |
| Q34180539 | One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. |
| Q46098987 | Overview of migraine treatment |
| Q57165507 | Paediatric migraine: evidence-based management and future directions |
| Q24656535 | Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence |
| Q37363486 | Perimenstrual headache: treatment options |
| Q37973436 | Pharmacological synergy: the next frontier on therapeutic advancement for migraine |
| Q36984540 | Predictors of Triptan Response in Pediatric Migraine |
| Q86606657 | Primary Headache Disorders: Focus on Migraine |
| Q50758391 | Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial. |
| Q57024024 | Publication committees in clinical trials in headache |
| Q40668216 | Quality-by-design-based ultra high performance liquid chromatography related substances method development by establishing the proficient design space for sumatriptan and naproxen combination |
| Q50265031 | Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine |
| Q40014461 | Recent advances in the pharmacological management of migraine |
| Q92890313 | Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials |
| Q38018216 | Role of dexamethasone in the prevention of migraine recurrence in the acute care setting: a review |
| Q50086116 | Similarities and Differences Between Migraine in Children and Adults: Presentation, Disability, and Response to Treatment |
| Q39220850 | SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study |
| Q24203707 | Sumatriptan (oral route of administration) for acute migraine attacks in adults |
| Q24202970 | Sumatriptan plus naproxen for acute migraine attacks in adults |
| Q24185878 | Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults |
| Q39255809 | Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study |
| Q33755782 | Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal |
| Q42614801 | Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention |
| Q93701445 | Sumatriptan-naproxen works well for migraine |
| Q38656208 | Sumatriptan/Naproxen Sodium: A Review in Migraine |
| Q37256688 | Sumatriptan/naproxen sodium combination for the treatment of migraine |
| Q37127566 | Sumatriptan/naproxen sodium combination versus its components administered concomitantly for the acute treatment of migraine: a pragmatic, crossover, open-label outcomes study |
| Q39219303 | Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study |
| Q38126370 | Sumatriptan/naproxen sodium: a review of its use in adult patients with migraine |
| Q38066258 | Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine |
| Q45978359 | Telcagepant is a new oral treatment for migraine. |
| Q47840827 | The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial |
| Q38323922 | The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies |
| Q43136690 | The future of migraine: beyond just another pill |
| Q37340160 | The pharmacological management of migraine, part 1: overview and abortive therapy |
| Q39983756 | The triptans |
| Q84979030 | Therapeutic guidelines for headache |
| Q38392414 | Therapeutic prospects for migraine: can paradise be regained? |
| Q52139335 | Thermoreversible nanoethosomal gel for the intranasal delivery of Eletriptan hydrobromide. |
| Q35658657 | Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders |
| Q33987376 | Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan |
| Q38002459 | Treating pediatric migraine: an expert opinion. |
| Q42907018 | Treatment of acute migraine in the pediatric population |
| Q86590269 | Treatment of pediatric migraine |
| Q36925907 | Treatment of pediatric migraine in the emergency room |
| Q37229791 | Treatment recommendations for migraine |
| Q38994955 | Triptans and migraine: advances in use, administration, formulation, and development |
| Q42906989 | Triptans: Where Things Stand |
| Q43815819 | Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes |
| Q36518248 | Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment |
| Q36260684 | What can be learned from the history of recurrence in migraine? A comment |
Search more.